p53 mediates failure of human definitive hematopoiesis in dyskeratosis congenita by Fok, Wilson Chun et al.




p53 mediates failure of human definitive
hematopoiesis in dyskeratosis congenita
Wilson Chun Fok
Washington University School of Medicine in St. Louis
Evandro Luis de Oliveira Niero
Washington University School of Medicine in St. Louis
Carissa Dege
Washington University School of Medicine in St. Louis
Kirsten Ann Brenner
Washington University School of Medicine in St. Louis
Christopher Michael Sturgeon
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Fok, Wilson Chun; Niero, Evandro Luis de Oliveira; Dege, Carissa; Brenner, Kirsten Ann; Sturgeon, Christopher Michael; and Batista,




Wilson Chun Fok, Evandro Luis de Oliveira Niero, Carissa Dege, Kirsten Ann Brenner, Christopher Michael
Sturgeon, and Luis Francisco Zirnberger Batista
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6067
Stem Cell Reports
Report
p53 Mediates Failure of Human Definitive Hematopoiesis in Dyskeratosis
Congenita
Wilson Chun Fok,1 Evandro Luis de Oliveira Niero,1 Carissa Dege,1 Kirsten Ann Brenner,1
Christopher Michael Sturgeon,1,2,3,* and Luis Francisco Zirnberger Batista1,2,3,*
1Department of Medicine
2Department of Developmental Biology
3Center of Regenerative Medicine
Washington University in St. Louis, St. Louis, MO 63110, USA
*Correspondence: csturgeon@wustl.edu (C.M.S.), lbatista@wustl.edu (L.F.Z.B.)
http://dx.doi.org/10.1016/j.stemcr.2017.06.015
SUMMARY
Dyskeratosis congenita (DC) is a bone marrow failure syndrome associated with telomere dysfunction. The progression and molecular
determinants of hematopoietic failure in DC remain poorly understood. Here, we use the directed differentiation of human embryonic
stem cells harboring clinically relevant mutations in telomerase to understand the consequences of DC-associated mutations on the
primitive and definitive hematopoietic programs. Interestingly, telomere shortening does not broadly impair hematopoiesis, as primitive
hematopoiesis is not impaired in DC cells. In contrast, while phenotypic definitive hemogenic endothelium is specified, the endothelial-
to-hematopoietic transition is impaired in cells with shortened telomeres. This failure is caused by DNA damage accrual and is mediated
by p53 stabilization. These observations indicate that detrimental effects of telomere shortening in the hematopoietic system are specific
to the definitive hematopoietic lineages. This work illustrates how telomere dysfunction impairs hematopoietic development and creates
a robust platform for therapeutic discovery for treatment of DC patients.
INTRODUCTION
Dyskeratosis congenita (DC) is a bone marrow failure
(BMF) syndrome whereby patients have telomeres at, or
below, the first percentile in length when compared with
the rest of the population (Savage and Alter, 2009). Patients
with DC usually come to clinical attention during child-
hood and present with a triad of oral leukoplakia, reticular
skin pigmentation, and nail dystrophy. While these pa-
tients are at increased risk for developing leukemia and
solid tumors, BMF is the major cause of death in DC,
commonly in young adulthood (Wilson et al., 2014).
While the severity of DC varies across patients, more
than 85% of afflicted individuals have cytopenias in one
or more lineages in late childhood, and more than 95%
will develop pancytopenia by adulthood.
All mutations identified to date in DC occur in genes that
regulate different aspects of telomere maintenance (Arma-
nios and Blackburn, 2012). The active telomerase complex,
which is responsible for telomere elongation in vertebrates,
is composed of the reverse transcriptase TERT, the RNA
component of telomeraseTERC, theTERC-stabilizingnucle-
olarproteinDKC1, andTCAB1,which is responsible for telo-
merasebiogenesis and trafficking (Schmidt andCech,2015).
Due to the tight regulationofTERTexpression, telomerase is
only active in stem and progenitor cells (including hemato-
poietic stem cells [Morrison et al., 1996; Yui et al., 1998]),
which suggests that DC is caused by a stem cell failure in
highly proliferative tissues, including the bone marrow.
Although there has been extensive biochemical charac-
terization of telomere maintenance mechanisms and their
role in maintaining genomic integrity, the connection
between telomere dysfunction and the specific clinical
phenotypes of BMF in DC patients remains poorly under-
stood. Patient samples are rare and cannot address the
effect of telomere deficiency on the genesis of tissue failure
that occurs during hematopoietic development. Here, we
characterize the primitive and definitive hematopoietic
development of isogenic human embryonic stem cells
(hESCs) carrying disease-associated mutations in the telo-
merase components TERT and DKC1, two of the most
commonly mutated genes in DC (Armanios and Black-
burn, 2012). We show that telomerase expression levels
are highly regulated during hESC differentiation toward
hematopoietic progenitors, with reduced TERT expression
within mesoderm, but restored TERT levels in hematopoi-
etic progenitors. Telomere shortening causes an increase
in primitive hematopoietic potential but significantly ab-
lates definitive hematopoietic potential. Furthermore, we
demonstrate that p53 mediates the effects of telomere
shortening on definitive hematopoiesis, which can be
rescued by inhibition of DNA damage signaling or by reac-
tivation of telomerase. Our findings elucidate telomerase
regulation patterns during early blood development, indi-
cate a role of DNA damage-induced p53 signaling in he-
matopoietic specification, and demonstrate the value of
in vitro hematopoietic differentiation to study the patho-
genesis of BMF in DC patients.
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RESULTS
Engineered hESCs Harboring DC-Associated
Mutations Have Impaired Telomere Maintenance
To study hematopoietic failure in cells harboring common
DC-associated mutations, we generated DKC1_A353V and
TERT_P704S mutant hESCs using CRISPR/Cas9-mediated
genome editing (Figures 1A–1C). Cells retained expres-
sion of pluripotency markers (Figure 1D) and had no chro-
mosomal abnormalities (Figure S1A). We then analyzed
the consequences of these mutations on the expression
of telomerase components. As expected, TERT expression
remained the same in both mutant cell lines while TERC
expression was significantly reduced in DKC1_A353V
hESCs (Figure 1E), as dyskerin is necessary for TERC stabili-
zation (Mitchell et al., 1999). No difference was observed in
the expression of dyskerin and shelterin components in
both DKC1_A353V and TERT_P704S hESCs (Figure S1B).
Importantly, telomere repeat amplification assays (TRAP,
Figure 1F) showed that telomerase activity, in comparison
with wild-type control, is reduced by approximately 75%
in DKC1_A353V and TERT_P704S hESCs. While DC hESCs
did exhibit subtle changes in cell-cycle distribution (Figures
S1C and S1D), they do not show apoptosis induction (Fig-
ures S1E–S1G), in contrast with hESCs to full deletion of
telomerase (Sexton et al., 2014), suggesting that hESCs
with residual telomerase activity behave differently from
those completely lacking telomerase activity. To confirm
this hypothesis, we created hESCs completely lacking
TERC (TERC/; Figure S2H). Accordingly, these cells un-
dergo robust apoptosis induction in culture (Figure S2I),
similar to TERT/ hESCs (Sexton et al., 2014). Combined,
these data suggest that phenotypes caused by disease-asso-
ciated mutations in telomerase cannot be recapitulated by
complete knockout of telomerase components.
Importantly, both DKC1_A353V and TERT_P704S hESCs
have significantly impaired telomere maintenance (Fig-
ure 1G), the major characteristic of telomere syndromes.
Telomere length in DKC1_A353V and TERT_P704S hESCS
averaged <4 kb at passage 30 (compared with >10 kb in the
isogenic, parental wild-type; Figure 1G). Collectively, these
results indicate that the DKC1_A353V and TERT_P704S
point mutations interfere directly with the catalytic activity
of telomerase, similar to what is observed in patients. Thus,
hESCs harboring patient-specific mutations allow us to
directly interrogate the consequences of telomere dysfunc-
tion during human tissue development in vitro.
Telomerase Expression Is Stringently Regulated during
Human Mesoderm and Hematopoietic Development
While we and others have made great strides in demon-
strating that induced pluripotent stem cells (iPSCs) can
serve as a valuable resource to study the biochemical regu-
lation of mutant telomerase, intrinsic clonal variability
(Gu et al., 2015; Winkler et al., 2013) and conflicting re-
sults arising from different reprogramming methodologies
(Agarwal et al., 2010; Batista et al., 2011) have precluded
the use of these cells to understand hematopoietic dis-
ease development. Vertebrate hematopoietic development
comprises at least two distinctive hematopoietic programs:
a transient, erythro-myeloid restricted primitive hemato-
poietic program, and the definitive hematopoietic pro-
gram, which gives rise to all blood cell lineages found in
the adult (Medvinsky et al., 2011). Clinical symptoms of
DC are usually not present at birth, with patients not
having indications of in utero hematopoietic deficiency,
suggesting that aplastic anemia in DC clinically manifests
as defective postnatal definitive hematopoiesis. However,
most hESC/iPSC differentiation strategies to date have
yielded hematopoietic progenitors that are heterogeneous
for both programs (reviewed in Ditadi et al., 2017), con-
founding their use in studying the consequences of telo-
mere dysfunction during human definitive hematopoietic
development.
Wehave recentlydemonstrated that stage-specificmanip-
ulationof canonicalWNT-b-catenin signaling allows for the
generation of exclusively primitive or exclusively definitive
hematopoietic progenitors from hESCs (Figure 2A; Stur-
geon et al., 2014). This methodology gives rise to multipo-
tent NOTCH-dependent clonal definitive erythro-myelo-
lymphoid progenitors (Ditadi et al., 2015), a hallmark of
definitive hematopoiesis (Clements and Traver, 2013).
With this approach, we asked whether we could dissect
the consequences of dysfunctional telomere maintenance
in human definitive hematopoietic progenitors, indepen-
dently from primitive hematopoietic development.
We first asked whether we could detect telomerase
expression during hESC hematopoietic differentiation.
We analyzed the expression of the telomerase core compo-
nents TERT and TERC during early primitive and defini-
tive hematopoietic specification. Mesoderm harboring
primitive hematopoietic potential, identified by KDR and
CD235a expression, was efficiently obtained on day 3 of
differentiation (Figure S2A) following WNT inhibition. By
day 8 of differentiation, CD43+ primitive hematopoietic
progenitors were identified by flow cytometry (Figure S2A).
We isolated these different populations by fluorescence-acti-
vated cell sorting (FACS) and found that TERC expression
was sustained in all populations (Figure 2Bi). Intriguingly,
TERT was transiently repressed in primitive hematopoietic
mesoderm, but then its expression was restored in CD43+
primitive hematopoietic progenitors (Figure 2Bii).
Similarly, KDR+CD235amesoderm harboring definitive
hematopoietic potential was efficiently obtained on day 3
of differentiation (Figure S2A) following WNT activation,
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Figure 1. Generation of Isogenic hESCs Harboring DC-Associated Mutations
(A) Model depicting the telomerase complex with specific amino acid modifications in red: DKC1_A353V and TERT_P704S. Diseases
associated with these mutations are described in blue.
(B) Strategy for introduction of disease-specific mutations in DKC1 and TERT. Guide RNAs (gRNAs) targeting exon 11 (DKC1) and exon 5
(TERT) were used in combination with specific single-strand DNA donor oligo templates for introduction of DKC1 (A353V; C/ T) and TERT
(P704S; C/ T). In blue are silent mutations introduced to facilitate CRISPR/Cas9-mediated genome modification.
(C) Sequencing traces confirming genome modification: red boxes indicate nucleotide modifications that lead to the desired amino acid
change. Blue box in TERT indicates a silent mutation introduced for increased genome-editing efficiency.
(D) Quantification of SOX2, OCT4, and NANOG levels by qRT-PCR analysis.
(E) Quantification of TERC and TERT expression by qRT-PCR in wild-type and telomerase-mutant hESCs. Expression is shown relative to
parental, wild-type cells. Data are plotted as mean ± SEM, n = 3 independent experiments. *p% 0.05, Student’s t test.
(F) Telomerase activity by TRAP in wild-type, DKC1_A353V, and TERT_P704S mutants. Range of concentrations represents 4-fold serial
dilutions. L.C., loading control; negative control: NP40 buffer.
(G) Telomere length analysis by telomere restriction fragment (TRF) of wild-type, DKC1_A353V, and TERT_P704S hESCs at different cell
passages, demonstrating progressive telomere shortening in mutant cells. Molecular weight is shown on the left.
WT, wild-type. See also Figure S1.
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Figure 2. Progressive Telomere Shortening Differentially Regulates Primitive and Definitive Hematopoietic Specification
(A) Schematic of in vitro definitive and primitive hematopoietic differentiation. WNT modulation at day 2 of differentiation determines
primitive or definitive hematopoietic specification. WNT activation is achieved by treatment with the WNT agonist CHIR99021, and WNT
(legend continued on next page)
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which then gave rise to a CD34+CD43CD73CD184
hemogenic endothelial population (Figure S2A).When iso-
lated and further cultured under hemato-endothelial con-
ditions, this definitive population gives rise to CD45+
definitive hematopoietic progenitors (Choi et al., 2012;
Ditadi et al., 2015). After these populations were isolated
by FACS, we observed that TERC expression was retained
in all populations (Figure 2Biii). Similar to what was
observed in primitivemesoderm, TERT levels were strongly
reduced in mesoderm harboring definitive hematopoietic
potential (Figure 2Biv), indicating that canonical WNT
signaling had no effect on TERT expression. However,
following this transient repression,TERTexpressionwithin
hemogenic endothelium, and its resultant CD45+ defini-
tive hematopoietic progenitors, was significantly upregu-
lated (Figure 2Biv). When taken together, these observa-
tions indicate that TERT expression is highly regulated
duringmesoderm/blood development, with robust telome-
rase expression being a conserved characteristic of both
primitive and definitive hematopoietic progenitors, high-
lighting the importance of telomere maintenance during
hematopoiesis.
Telomere Attrition Specifically Impairs Definitive
Hematopoiesis in DC
With this in vitro model to study the role of telomerase
during hematopoietic development, we differentiated
our DC hESCs toward primitive and definitive hemato-
poietic progenitors (Figure 2A). Telomere shortening
did not affect the specification of mesoderm, as late-pas-
sage DKC1_A353V and TERT_P704S hESCs gave rise to
KDR+CD235a+ (primitive) and KDR+CD235a (definitive)
mesodermal populations with efficiency similar to that
of wild-type hESCs (Figures S2B and S2C). However, we
observed striking differences at later times in hematopoiet-
ic development. In comparison with wild-type cells and
early-passage (longer telomeres) DC hESCs, late passage
(shorter telomeres) had significantly enhanced CD43+
primitive hematopoietic progenitor expansion (Figures
S2D and S2E) and primitive erythroid colony-forming cell
potential (EryP-CFC; Figures 2Ci and 2Di). These observa-
tions indicate that telomere shortening does not broadly
abrogate hematopoietic differentiation potential, as DC
hESCs with short telomeres are still able to efficiently
generate primitive hematopoietic progenitors.
Similarly, early stages of definitive hematopoietic spe-
cification were not affected by telomere shortening, as
early- and late-passage DKC1_A353V and TERT_P704S
hESCs generated a CD34+CD43 population on day 8 of
differentiation with efficiency similar to that of control
hESCs (Figure S3A). From these, we isolated the definitive
CD34+CD43 population and cultured them under hem-
ato-endothelial conditions, to assess their ability to undergo
theendothelial-to-hematopoietic transitionandyielddefin-
itive erythro-myeloid progenitors (Ditadi et al., 2015).
Strikingly, late-passage DKC1_A353V and TERT_P704S
hESCs exhibited a severe defect in definitive hematopoietic
potential, giving rise to approximately 5-fold less defini-
tive erythroid burst-forming units (BFU-E), and 3-fold less
myeloid colony-forming units (CFU-M) when compared
with wild-type or DC hESCs in early passage (Figures 2Cii
and 2Dii). Furthermore, while these cells still retained
the ability to give rise to CD4+CD8+ T cell progenitors (Fig-
ure 2E), late-passage DC hESCs exhibited a severe reduction
in cellularity, suggesting that definitive hematopoiesis is
impaired with progressive telomere shortening. The defini-
tivehematopoieticprofileof ourdifferentiationswas further
confirmed by their hemoglobin expression profile (Fig-
ure S3B). Importantly, the difference observed is not caused
by differential regulation of WNT canonical activity be-
tween wild-type and DC mutant cells, as treatment with
CHIR and IWP2 led to identical levels of activation/repres-
sion of the WNT target gene AXIN2 at day 3 of differentia-
tion, between the wild-type and different isogenic lines
repression is achieved by treatment with the WNT antagonist IWP2. Mesoderm specification is assessed at day 3 by flow-cytometric analysis
of KDR and CD235a expression. During definitive hematopoietic specification, hemogenic endothelium (H&E) is identified at day 8 of
differentiation as a CD34+CD43CD184CD73 population. CD45+ cells are identified after isolated day-8 H&E cells undergo an endo-
thelial-to-hematopoietic transition. For primitive hematopoietic specification, CD43+ cells are observed beginning at day 8.
(B) TERC and TERT expression during primitive (i and ii) and definitive (iii and iv) hematopoietic specification, as measured by qRT-PCR
from isolated populations, as in (A). n = 3 independent experiments; mean ± SEM. *p% 0.05, Student’s t test.
(C) Primitive EryP-CFC (i) and definitive colony-forming cell (ii) potential of DKC1_A353V and TERT_P704S hESCs in early passages
(indicated in the figure).
(D) Primitive Ery-P-CFC (i) and definitive colony-forming cell (ii) potential of DKC1_A353V and TERT_P704S hESCs in late passages
(indicated in the figure). n = 3 independent experiments; mean ± SEM. *p% 0.05, Student’s t test.
(E) T cell potential of CD34+CD43 populations derived from wild-type, DKC1_A353V, and TERT_P704S hESC lines at early or late passages
(indicated in the figure), obtained following CHIR99021 treatment. T cell potential is assessed by the development of CD4+CD8+ cells
within a CD45+CD56 gate following culture on OP9-DL4 stromal cells for 28 days. CD56 and CD45 are compared on the left with number of
events shown for CD45+CD56. On the right is the subset of cells that were CD45+CD56, and the percentage of CD4 versus CD8 cells is
shown.
WT, wild-type. See also Figures S2 and S3.
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(Figure S3C). Combined, these observations suggest that
progressive telomere shortening in telomerase-mutant
hESCs causes a specific impairment of definitivehematopoi-
etic potential, which may share similar mechanism(s) with
the severe pancytopenia observed in DC patients.
p53 Stabilization Mediates Hematopoietic Failure in
DC Cells
Next, we interrogated the mechanism behind the differen-
tial regulation of hematopoiesis in hESCs with dysfunc-
tional telomeres. Telomere uncapping due to progressive
telomere shortening is a potent inducer of DNA damage.
Accordingly, we detected phosphorylated H2AX (gH2AX)
accumulation in DKC1_A353V and TERT_P704S hESCs
in late passage (Figure 3A). Additionally we observed a
cumulative increase in p53 levels in DC-mutant hESCs
with progressively shorter telomeres (Figures 3B and S4A),
a hallmark of cells harboring dysfunctional telomeres
(Palm and de Lange, 2008). As p53-dependent DNA dam-
age response causes BMF inmurinemodels of Fanconi ane-
mia (Ceccaldi et al., 2012), we hypothesized that telomere
dysfunction-mediated p53 stabilization could also regulate
the specification of hematopoiesis in hESCs. To test this
hypothesis, we ablated p53 in our DKC1_A353V hESCs
(DKC1_A353V_p53/; Figures S4B–S4D). Similar to those
with functional p53, these hESCs continue to exhibit pro-
gressive telomere shortening with extended passage, as
telomerase activity remains impaired (Figure 3C).
We observed that primitive hematopoietic potential
was restored to normal levels following p53 deletion, as
late-passage DKC1_A353V_p53/ hESCs exhibited signif-
icantly less CD43+ primitive hematopoietic progenitors
(Figures 3D and 3E) and concomitant EryP-CFC potential
(Figure 3F). Conversely, when we specified these hESCs
toward definitive hematopoiesis, we observed that defini-
tive hematopoietic potential was restored in late-passage
DKC1_A353V_p53/ hESCs, as they gave rise to definitive
erythro-myeloid and lymphoid progenitors (Figures 3G
and S4E) with efficiency similar to that of controls. Further-
more, this functional increase in definitive hematopoi-
esis was not due to an increase in phenotypic hemogenic
endothelium specification, as there was no increase in
the observed CD34+CD43CD73CD184 population in
DKC1_A353V_p53/ cells compared with DKC1_A353V
cells (Figures 3H and 3I). Taken together, these data estab-
lish p53 as a regulator of human hematopoietic potential,
eliciting positive and negative effects on primitive and
definitive hematopoiesis, respectively.
Telomerase Reactivation Rescues Definitive
Hematopoietic Specification in DC Mutants
Currently, DC has no cure. However, murine models have
shown that reactivation of telomerase is able to rescue ho-
meostasis across different tissues in telomerase-mutant
mice (Bar et al., 2016; Jaskelioff et al., 2011). We therefore
asked whether telomerase reactivation via genetic correc-
tion could restore human definitive hematopoietic poten-
tial in DC hESCs. Moreover, by specifically restoring TERC
levels in hESCs that retain mutant dyskerin, defects caused
specifically by telomere dysfunction can be isolated from
defects potentially caused by dyskerin’s role in ribosomal
biology (Meier, 2005). We therefore inserted a U3-driven
TERC within the AAVS1 ‘‘safe-harbor’’ locus (Hockemeyer
et al., 2009; Sim et al., 2015), creating DKC1_A353V +
TERC hESCs (Figure 4A). Both TERC expression levels (Fig-
ure 4B) andTRAP analysis (Figure 4C) indicate restored telo-
merase activity, which is corroborated by a significant
increase of telomere length in DKC1_A353V + TERC hESCs
(Figure 4D). We next differentiated these hESCs toward
primitive and definitive hematopoiesis. As observed with
p53 deletion, telomerase reactivation decreased primitive
hematopoietic potential (Figures 4E–4G) and successfully
restored definitive erythro-myeloid potential in late-pas-
sage DKC1_A353V hESCs (Figure 4H). Thus, reactivation
of telomerase can restore normal primitive and definitive
hematopoietic output in DC hESCs.
DISCUSSION
The results presented here demonstrate the essential role
of telomerase during human hematopoietic develop-
ment. Our stage-specific directed differentiation approach
demonstrated that telomere shortening elicits a differential
effect on primitive and definitive hematopoiesis, mediated
by p53.
While a positive role of p53 in erythropoietic differentia-
tion has been observed during malignant hematopoietic
differentiation (Molchadsky et al., 2010), our results indi-
cate that p53 can also regulate non-malignant hemato-
poietic development. Our observed near-complete failure
of definitive hematopoietic output from phenotypic he-
mogenic endothelium, which is restored by p53 deletion,
suggests that p53 directly regulates definitive hematopoiet-
ic potential in DC cells. Hemogenic endothelium is the
direct precursor to the hematopoietic stem cell (Julien
et al., 2016), raising the possibility that our observations
and clinical BMF may both be due to conserved mecha-
nism(s) governed by p53. As our understanding of human
definitive hemogenic endothelium improves, we will be
able to better define the role of p53 in this complex devel-
opmental process.
Importantly, while telomerase-deficient mice have
abnormal blood phenotypes, overt cytopenias due to telo-
mere dysfunction have never been fully recapitulated in
murine models (Calado and Young, 2008), which suggests


































































































































































































































































































Figure 3. DNA Damage Accrual and p53 Stabilization Impair Definitive Hematopoietic Development in DC Cells
(A) Representative immunoblot analysis of gH2AX in wild-type and mutant hESCs at different cell passages.
(B) Representative immunoblot analysis of p53 levels in DKC1_A353V (i) and TERT_P704S (ii) hESCs with progressive cell passage number
(P.N.). GAPDH is shown as loading control.
(C) Telomere length analysis by TRF of wild-type, DKC1_A353V, and DKC1_A353V_p53/ hESCs at different passages.
(D) Representative flow-cytometric analysis of CD34 and CD43 expression in day-11 differentiation cultures treated with IWP2, as in
Figure 2A. In red, population of interest.
(E) Quantification of CD43+ population obtained from day-11 differentiation cultures treated with IWP2, as in (D).
(F) Primitive erythroid colony-forming cell (EryP-CFC) potential in day-11 differentiation cultures, treated with IWP2 as in (D).
(G) Colony-forming cell potential of definitive hematopoietic progenitors, generated as in Figure 2A.
(H) Representative flow-cytometric analysis of CD73 and CD184 expression within CD34+CD43 cells. In red, population of interest.
(I) Quantification of CD34+CD43CD73CD184 population, as in (H).
In all panels, wild-type (WT) is compared with DKC1_A353V (p66) and DKC1_A353V_p53/ (p70) hESCs. n = 3 independent experiments,
mean ± SEM; *p% 0.05; Student’s t test. NS, not significant. See also Figure S4.


















































































































































































































Figure 4. Telomerase Reactivation Restores Hematopoietic Potential in DKC1_A353V hESCs
(A) Model of AAVS1 targeting in DKC1_A353V hESCs.
(B) Quantification of TERC levels by qRT-PCR in wild-type, DKC1_A353V, and DKC1_A353V + TERC hESCs.
(C) TRAP analysis measuring telomerase activity in wild-type, DKC1_A353V, and DKC1_A353V + TERC hESCs. Range of concentrations
represents 4-fold serial dilutions. L.C., loading control; negative control: NP40 buffer.
(D) Telomere length analysis by TRF of wild-type, DKC1_A353V, and DKC1_A353V + TERC hESCs.
(E) Representative flow-cytometric analysis of CD34 and CD43 expression in day-11 differentiation cultures treated with IWP2, as in
Figure 2A. In red, population of interest.
(F) Quantification of CD43+ population obtained from day-11 differentiation cultures treated with IWP2, as in (E).
(legend continued on next page)
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that our observed pan-hematopoietic defect specifically
in definitive derived lineages more broadly recapitulates
that found in patients. While the exact mechanism(s) ex-
erted by p53 in the regulation of definitive hematopoiesis
remains elusive, this in vitro platform of hematopoietic
differentiation can be used to address this question.
Importantly, however, DC patients are clinically diverse
in terms of genetic mutations, inherited telomere length,
age of onset, and disease severity. Therefore, it remains to
be demonstrated that p53 activation is a universal marker
for hematopoietic failure in this disease.
The ability to restore hematopoietic output by reactiva-
tion of telomerase lends further support for recent clinical
trials demonstrating that increased telomerase function
has a positive effect on hematopoiesis in adult aplastic
anemia patients (Townsley et al., 2016). Our observations
suggest that similar approachesmay be used inDC children
suffering from hypoplastic marrow. Moreover, the restora-
tion of hematopoietic potential in DKC1 mutant hESCs
by rescuing TERC levels, while not interfering with dysker-
in’s role in ribosomal biology (Meier, 2005), conclusively
establishes X-linked DC as a telomere-dysfunction disease.
Together, these results provide evidence that human
BMF syndromes can be modeled in vitro, by directed dif-
ferentiation strategies of human PSCs that recapitulate
in vivo development. This opens the exciting possibility
of identifying novel therapeutics against BMF in a high-
throughput, controlled manner.
EXPERIMENTAL PROCEDURES
Human Embryonic Stem Cells
H1 (WA01) hESCs were acquired from the WiCell Research Insti-
tute (Madison, WI), following all institutional guidelines deter-
mined by the Embryonic StemCell ResearchOversight Committee
(ESCRO) at Washington University. hESCs were routinely cultured
withmouse embryonic fibroblasts (MEFs) that had been previously
g-irradiated (30 Gy). The cellular passages described as ‘‘early’’
represent the shortest telomeres that still allow efficient hemato-
poietic differentiation.
Generation of Isogenic Telomerase-Mutant hESCs
DKC1_A353V (X-linked), TERT_P704S (homozygous mutation),
DKC1_A353V_p53/, and TERC/ were generated using CRISPR/
Cas9 genome-editing technology. CRISPR guides were designed us-
ing theMassachusetts Institute of Technology (MIT) CRISPRDesign
tool (http://crispr.mit.edu/) and generated as described previously
(Ran et al., 2013).
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